neuropathic pain

Can cannabis succeed where other compounds have failedUse of a novel semi-fluorinated alkane drug delivery technology as a vehicle to deliver cannabinoids to the ocular surface reached target tissues without systemic side effects in preclinical studies.
Testing at point of care for improved patient satisfaction, re-treatment ratesAfter spending a few months testing for dry eye and treating the tear film before doing preoperative measurements, the re-treatment rate dropped from 11% to 3%.
What's in the pipeline for 2014?Analysts expect to see key developments in categories that include cancer, heart failure, obesity and diabetes, and hepatitis C. They also look toward some greatly needed antibiotics to deploy in the war against superbugs.
Focus on tapentadol: Role in the treatment of neuropathic painNeuropathic pain is a difficult-to-treat condition; pathologic changes in neuronal pathways may result in suboptimal analgesic control with opioid agents alone. Polypharmacy is employed often to simultaneously target multiple levels of the pain pathway, at the expense of escalated complexity of drug regimens and risk for drug–drug interactions and adverse effects. Tapentadol combines 2 mechanisms of action within a single molecule, allowing for mu-receptor activation and norepinephrine reuptake inhibition without the aforementioned drawbacks of multiple agent regimens. Recently approved in its extended-release formulation with favorable pharmacokinetics and improved gastrointestinal tolerance over pure opioids, tapentadol may prove cost effective when productivity and indirect costs are considered.